Background/Objective: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by diverse clinical manifestations. However, variations in its clinical presentations across different ages, genders, anatomical sites, and seasons remain incompletely understood. The objective was to explore the clinical heterogeneities of AD using data from the Chinese non-selective registration system. Methods: A prospective analysis was conducted on 3829 AD patients enrolled in the Chinese Non-selective Registry for AD (CNRAD) at hospital settings from 2020 to 2022. Demographic profiles; distribution, type, and severity of the skin lesion; laboratory findings; allergic comorbidities; family history; and exacerbating factors were analyzed. Results: The male-to-female ratio was 0.92 among adolescent and adult AD patients but increased to 2.11 in elderly AD patients, highlighting an age-dependent gender difference in AD prevalence. Age groups displayed distinct anatomical preferences for lesion distribution, with reduced involvement of the cubital and popliteal fossae in adult and elderly patients. Based on skin lesion characteristics, ten clinical subtypes of AD were proposed. Elderly AD patients exhibited higher severity, compared to adolescence and adult AD patients, with male patients being more severe than females. Elderly AD patients showed a lower proportion of extrinsic type, compared to childhood AD patients. Seasonal change emerged as the most important factor triggering AD flares. Conclusions: This study provides new insights into the heterogeneities of AD clinical manifestations in the Chinese population, demonstrating their significant dependence on temporal factors, including age and season.

Background: Abrocitinib has shown significant efficacy and safety in clinical trials for moderate‐to‐severe atopic dermatitis (AD), but long‐term real‐world data are scarce. Objective: To assess the long‐term efficacy, predictors of response, and safety profiles associated with abrocitinib treatment in a real‐world setting. Methods: This prospective study enrolled 147 moderate‐to‐severe AD patients, and physician‐ and patient‐reported outcomes were evaluated at multiple time points. Results: Abrocitinib rapidly reduced Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), Itch Numeric Rating Scale (Itch‐NRS), and body surface area (BSA) from Week 4 throughout Week 52, with 83.1% and 53.2% of patients achieving EASI‐75 and EASI‐90, respectively, at Week 52. Improvement was less pronounced in the head and neck compared to the trunk and limbs. Shorter disease duration (<   84 months) and the absence of allergic comorbidities predicted better long‐term response. Patients achieving EASI‐75 or EASI‐90 by Week 4 were more likely to maintain control at Week 52. Drug survival was 72.7% at Week 52. Adverse events (AEs) occurred in 61.9% of patients, with acneiform eruptions (19.7%) and gastrointestinal symptoms (17.7%) being most common within Week 12. After 12 weeks, hypercholesterolemia, abnormal liver function, and infections increased. Conclusion: Abrocitinib showed promising long‐term efficacy and safety in Chinese patients with moderate‐to‐severe AD, while consistent lab monitoring is required. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2200063195